Your browser doesn't support javascript.
loading
Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
Parquet, A; Laurian, Y; Rothschild, C; Navarro, R; Guérois, C; Gay, V; Durin, A; Peynet, J; Sultan, Y.
Affiliation
  • Parquet A; Haemophilia Centre of ETS-Lille, France.
Thromb Haemost ; 82(4): 1247-9, 1999 Oct.
Article in En | MEDLINE | ID: mdl-10544907
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Factor IX / Hemophilia B / Antibodies Type of study: Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Child / Child, preschool / Humans / Infant Language: En Journal: Thromb Haemost Year: 1999 Document type: Article Affiliation country: Francia Country of publication: Alemania
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Factor IX / Hemophilia B / Antibodies Type of study: Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Child / Child, preschool / Humans / Infant Language: En Journal: Thromb Haemost Year: 1999 Document type: Article Affiliation country: Francia Country of publication: Alemania